Research ArticleOriginal Article

Surgical treatment of intrahepatic cholangiocarcinoma: a retrospective study of 104 cases

Xiao-Dong Xun and Qiang Li
Cancer Biology & Medicine December 2016, 13 (4) 469-473; DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0063

References

  1. 1.↵
    2. Brown KM,
    3. Parmar AD,
    4. Geller DA.
    Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014; 23: 231–46.
    OpenUrlCrossRefPubMed
  2. 2.
    2. Bagante F,
    3. Gani F,
    4. Spolverato G,
    5. Xu L,
    6. Alexandrescu S,
    7. Marques HP, et al.
    Intrahepatic cholangiocarcinoma: prognosis of patients who did not undergo lymphadenectomy. J Am Coll Surg. 2015; 221: 1031–40.e4.
    OpenUrl
  3. 3.
    2. Sakamoto Y,
    3. Kokudo N,
    4. Matsuyama Y,
    5. Sakamoto M,
    6. Izumi N,
    7. Kadoya M, et al.
    Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer. 2016; 122: 61–70.
    OpenUrl
  4. 4.↵
    2. Spolverato G,
    3. Ejaz A,
    4. Kim Y,
    5. Sotiropoulos GC,
    6. Pau A,
    7. Alexandrescu S, et al.
    Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2014; 18: 1284–91.
    OpenUrl
  5. 5.↵
    2. Bridgewater J,
    3. Galle PR,
    4. Khan SA,
    5. Llovet JM,
    6. Park JW,
    7. Patel T, et al.
    Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60: 1268–89.
    OpenUrlCrossRefPubMed
  6. 6.
    2. Horino K,
    3. Beppu T,
    4. Komori H,
    5. Masuda T,
    6. Hayashi H,
    7. Okabe H, et al.
    Evaluation of mass-forming intrahepatic cholangiocarcinoma with viral hepatitis. Hepatogastroenterology. 2012; 59: 1217–9.
    OpenUrlPubMed
  7. 7.↵
    2. Uchino K,
    3. Tateishi R,
    4. Fujiwara N,
    5. Minami T,
    6. Sato M,
    7. Enooku K, et al.
    Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients. Hepatol Res. 2016; 46: 259–68.
    OpenUrl
  8. 8.
    2. Chekhun SV,
    3. Lukyanova NY,
    4. Shvets YV,
    5. Burlaka AP,
    6. Buchinska LG.
    Significance of ferritin expression in formation of malignant phenotype of human breast cancer cells. Exp Oncol. 2014; 36: 179–83.
    OpenUrl
  9. 9.↵
    2. Usnarska-Zubkiewicz L,
    3. Strutyńska-Karpińska M,
    4. Zubkiewicz-Kucharska A,
    5. Zarebski P,
    6. Grabowski K.
    Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report. Adv Clin Exp Med. 2014; 23: 959–67.
    OpenUrl
  10. 10.↵
    2. Lin PY,
    3. Zhou XP,
    4. Chen ZS,
    5. Lyu LS,
    6. Tang ZH.
    Research advances on pathogenic mechanisms of HBV-related intrahepatic cholangiocarcinoma. Chin J Hepatobiliary Surg. 2014; 20: 617–20.
    OpenUrl
  11. 11.↵
    2. Li DY,
    3. Zhang HB,
    4. Yang N,
    5. Quan Y,
    6. Yang GS.
    Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients: results of a monocentric series. World J Gastroenterol. 2013; 19: 9084–91.
    OpenUrl
  12. 12.
    2. Zhang L,
    3. Bi XY,
    4. Zhao P.
    Advancement in surgical treatment of intrahepatic cholangiocarcinoma. Chin J Hepatobiliary Surg. 2010; 16: 718–20.
    OpenUrl
  13. 13.↵
    2. Choi SB,
    3. Kim KS,
    4. Choi JY,
    5. Park SW,
    6. Choi JS,
    7. Lee WJ, et al.
    The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009; 16: 3048–56.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Morine Y,
    3. Shimada M.
    The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics. J Gastroenterol. 2015; 50: 913–27.
    OpenUrl
  15. 15.↵
    2. Saxena A,
    3. Chua TC,
    4. Sarkar A,
    5. Chu F,
    6. Morris DL.
    Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg. 2010; 14: 1128–38.
    OpenUrlPubMed
  16. 16.↵
    2. Luo XW,
    3. Yuan L,
    4. Wang Y,
    5. Ge RL,
    6. Sun YF,
    7. Wei GT.
    Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study. J Gastrointest Surg. 2014; 18: 562–72.
    OpenUrlPubMed
  17. 17.↵
    2. Dhanasekaran R,
    3. Hemming AW,
    4. Zendejas I,
    5. George T,
    6. Nelson DR,
    7. Soldevila-Pico C, et al.
    Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 2013; 29: 1259–67.
    OpenUrl
  18. 18.↵
    2. Zhou QB,
    3. Lai DM,
    4. Lin Q,
    5. Chen YJ,
    6. Wang J,
    7. Chen JS, et al.
    Surgical management and prognosis of 80 cases with intrahepatic cholangiocarcinoma. Chin Arch Gen Surg (Electronic Edition). 2012; 6: 12–6.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords